SEC Form SC 13D/A filed by Heliogen Inc. (Amendment)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☒.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1

The percentages used herein and in the rest of this Schedule 13D calculated based on 5,908,645 shares of common stock outstanding as of November 9, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2023. The beneficial ownership information reported herein and the transaction information reported in Item 5 below reflects a 1-for-35 reverse stock split  of the Issuer’s Common Stock effected by the Issuer on  August 31, 2023.

CUSIP NO.

42329E105

EXPLANATORY NOTE

This Amendment No.4 (this “Amendment No. 4”) to the Statement on Schedule 13D (as amended, the “Statement”) is being filed with the Securities and Exchange Commission (the “Commission”) relating to the common stock, par value $0.0001 per share (the “Common Stock”) of Heliogen, Inc., a corporation organized under the laws of the state of Delaware (the “Issuer”). The beneficial ownership information reported herein and the transaction information reported in Item 5 below reflects a 1-for-35 reverse stock split  of the Issuer’s Common Stock effected by the Issuer on  August 31, 2023. This Amendment amends and supplements the Statement originally filed on February 13, 2023 with the Commission. Unless otherwise defined herein, capitalized terms used herein shall have the meanings ascribed thereto in the Statement. Except as otherwise provided herein, each Item of the Schedule 13D remains unchanged.

 

Item 5.

Interest in Securities of the Issuer.

PRIME MOVERS LAB  LLC

By:	/s/ Taylor Frankel
Name:	Taylor Frankel
Title:	Authorized Person

	/s/ Dakin Sloss
	Dakin Sloss